- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01488604
A Study of an Experimental Nasal Spray in Subjects With Early Signs of the Common Cold
Efficacy and Safety of an Antiviral Polymeric Nasal Spray: A Randomized, Parallel Group, Double-blind, Placebo-controlled Study in Subjects With Early Symptoms of Common Cold
This study will test 200 people to see if an experimental nasal spray has an effect on symptoms of the common cold if used when the symptoms start. At the first visit to the clinic, potential subjects will have tests to make sure they qualify to participate in the study.
If they qualify, they will have an equal chance of receiving the experimental nasal spray or a sham nasal spray (one that does not have the experimental formula). At the first visit, subjects will receive their assigned nasal spray and use it once at the clinic. They will also receive a booklet called a diary. Subjects will take the rest of their treatments for day 1 at home, and for the next six days, they will use the nasal spray four times per day and record their symptoms in the diary, as instructed. Then subjects will come back to the clinic for a final visit.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is an investigation in healthy subjects with early signs of common cold. Subjects will be randomly assigned in a 1:1 ratio to receive either Polymeric Nasal Spray or a matching placebo nasal spray.
Subjects will be screened for eligibility and randomized to treatment at the Screening/ Randomization Visit (Day 1). Subjects will apply the first dose of the nasal spray at this visit under supervision. The other applications will take place at home on Day 1. On Days 2 through 7, subjects will use their assigned nasal spray as 2 sprays per nostril, 4 times per day.
One Follow up Visit will be conducted within 3 days of the last application of nasal spray.
Enrollment will continue until 200 subjects have completed the investigation (100 per treatment group). The subject and the investigative staff will be blinded to the assigned nasal spray.
Efficacy will be measured, and recorded in the subject's diary, and safety will be assessed by reported AEs and ADEs.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Berkshire
-
Reading, Berkshire, United Kingdom, RG2 0TG
- Synexus Thames Valley
-
-
Llaishen
-
Cardiff, Llaishen, United Kingdom, CF14 5GJ
- Synexus Wales
-
-
Wales
-
Cardiff, Wales, United Kingdom, CF10 3AX
- Common Cold Center and Healthcare Clinical Trials
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Have early signs of a common cold: If female of child-bearing potential, have a negative pregnancy test at Screening.
- Have signed and dated the informed consent document, indicating that they have been informed of all pertinent aspects of the investigation
- Are willing and able to comply with scheduled visits, treatment plan, and other investigation procedures
Exclusion Criteria:
- Have had common cold or flu-like symptoms outside the protocol-specified parameters.
- Are current smokers as defined by the protocol.
- Have any medical history or condition or use any drug or device that (per protocol or in the opinion of the investigator) might compromise subject safety, participation in the trial, action of the investigational device, or results of the investigation..
- Are related to anyone involved with the conduct of the investigation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PNS
2 sprays of experimental nasal spray per nostril 4 times per day for 7 days
|
Experimental nasal spray
Other Names:
|
Sham Comparator: SNS
2 sprays of sham nasal spray per nostril 4 times per day for 7 days
|
Sham nasal spray
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Symptoms of the Common Cold
Time Frame: Within 7 days
|
Subjects will score their symptoms of the common cold including local symptoms (sore throat, blocked nose, runny nose, cough, and sneezing) and systemic symptoms (headache, muscle ache, and chilliness) on a scale of 0-3, where 0=: None (symptoms not present in the previous 24 hours) and 3= Severe (symptoms disturbing/irritating most of the time).
|
Within 7 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Effect of Common Cold on Daily Activities
Time Frame: Within 7 days
|
Subjects will score how their cold affects daily activities on a scale of 0-3, where 0= None (able to carry out daily activities as normal) and 3= Severe (very limited or no ability to carry out daily activities).
|
Within 7 days
|
Effect of Common Cold Symptoms on Sleep
Time Frame: Within 7 days
|
Subjects will score how their cold affects ability to sleep on a scale of 0-3, where 0= None (no effect on sleep) and 3= Severe (sleep severely affected, or sleep not possible).
|
Within 7 days
|
Number of Days Lost
Time Frame: Within 7 days
|
The number of days lost at school or work because of the common cold will be recorded in the subject diary.
|
Within 7 days
|
Treatment Outcome
Time Frame: Within 7 days
|
Treatment outcome will be recorded by the subject on the evenings of treatment days on a scale of 0-4, where 0=Complete recovery and 4=Deterioration.
|
Within 7 days
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- POCEXP0003
- CIV-GB-11-12-003243 (Other Identifier: MHRA)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Common Cold
-
Cardiff UniversityCompletedCommon Cold/FluUnited Kingdom
-
Perrigo CompanyGlaxoSmithKline; Pfizer; McNeil Consumer Healthcare Division of McNEIL-PPC, Inc. and other collaboratorsCompletedNasal Congestion Associated With the Common ColdUnited States
-
NovartisCompletedCommon Cold Associated With CoughCanada
-
Probi ABCompletedAcute Upper Respiratory Tract Infections (Common Cold)Italy
-
Ache Laboratorios Farmaceuticos S.A.Suspended
-
Beijing Da-an Bio-technology Co., Ltd.Unknown
-
Brainfarma Industria Química e Farmacêutica S/ATechtrials Pesquisa e Tecnologia Ltda; PharmagenixUnknown
-
NovartisCompletedSore Throat Due to a Common ColdGermany
-
Boehringer IngelheimCompleted
-
Lund UniversityCoradil ABEnrolling by invitation
Clinical Trials on Polymeric Nasal Spray
-
VistaGen Therapeutics, Inc.TerminatedSocial Anxiety DisorderUnited States
-
VistaGen Therapeutics, Inc.RecruitingSocial Anxiety DisorderUnited States
-
VistaGen Therapeutics, Inc.CompletedSocial Anxiety DisorderUnited States
-
University of ChicagoMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.Withdrawn
-
Viiral Nordic ABCompleted
-
Oyster Point Pharma, Inc.CompletedDry Eye DiseaseUnited States
-
Imperial College LondonGlaxoSmithKlineCompleted
-
Sara EspinozaThe University of Texas Health Science Center, Houston; The University of Texas... and other collaboratorsCompletedObesity | Sedentary Lifestyle | Sarcopenia | Aging | Sarcopenic ObesityUnited States
-
P & B GroupMediAxe CROCompletedAllergic RhinitisFrance
-
P & B GroupMediAxe CROTerminatedSARS-CoV-2 InfectionFrance